GlassScriptPhysician profile
Keshani Jain
NPI 1376557546
$3,889.47
in general payments reported to CMS, 2019-2025
29 companies · $1,410 in 2025
The $1,410 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $14.27 · 2021: $104 · 2022: $551 · 2023: $681 · 2024: $993 · 2025: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,083.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $932.92 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $407.25 | 2022-2025 | Tavneos, Krystexxa, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $278.20 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $201.65 | 2021-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $181.18 | 2023-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.33 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $150.17 | 2024-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $142.04 | 2021-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $133.38 | 2022-2025 | Tarpeyo |
| Novo Nordisk INC | $124.69 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Ardelyx, INC. | $120.05 | 2023-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $116.47 | 2023-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $113.05 | 2022 | |
| Travere Therapeutics, INC. | $110.27 | 2023-2025 | |
| Daiichi Sankyo INC. | $96.17 | 2022-2024 | Injectafer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $91.21 | 2019-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $77.72 | 2023-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $75.69 | 2023-2025 | Benlysta, Jesduvroq |
| Novartis Pharmaceuticals Corporation | $66.74 | 2023-2025 | |
| Scpharmaceuticals INC. | $56.25 | 2025 | |
| Akebia Therapeutics INC | $44.84 | 2022-2024 | Auryxia |
| Horizon Therapeutics Plc | $44.52 | 2021-2023 | Krystexxa |
| Apellis Pharmaceuticals, INC. | $36.48 | 2025 | Empaveli |
| Renalytix Ai, INC. | $30.81 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Kyowa Kirin, INC. | $30.26 | 2023-2024 | Crysvita |
| Esperion Therapeutics, INC. | $25.52 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.24 | 2021 | |
| Pharmacosmos Therapeutics INC. | $13.98 | 2022 | |
| Corcept Therapeutics | $13.39 | 2023 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keshani Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.